Chinook Therapeutics logo
Chinook Therapeutics KDNY
report update icon

Quarterly report 2023-Q2
added 11-21-2026

Chinook Therapeutics Revenue | KDNY

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Chinook Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
6.13 M 51.6 M 827 K 3.63 M 2.76 M 3.76 M 3.88 M 73 M 13.4 M 828 K - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
73 M 827 K 16 M

Quarterly Revenue Chinook Therapeutics

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
1.01 M 1.83 M 512 K 2.5 M 418 K 2.7 M 51.2 M 4 K 34 K 351 K -22.5 M 3.79 M 5.57 M 14 M 3.63 M 4.8 M 4.89 M 3.94 M 2.76 M 3.06 M 2.64 M 6.63 M 3.76 M 3.79 M 5.92 M 3.77 M 3.88 M 3.79 M 39 M 4.03 M 34.4 M 19.1 M 9.88 M 9.57 M 9.89 M 2.49 M 985 K 25 K - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
51.2 M -22.5 M 6.53 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
42.8 M - -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
5.21 M - - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
1.02 M - -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
4.98 M - 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
37.9 M - -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
41.1 M - - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
2.8 M - -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
39.6 M - - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
1.84 M - - $ 2.64 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
1 M - - $ 826 K usaUSA
Synlogic Synlogic
SYBX
8 K - - $ 7.07 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
100 K - -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
39.2 M - -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
52.1 M - - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
135 K - - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
19.6 M - 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
198 K - - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
303 M - - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
21.5 M - 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
65.3 M - 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
8.83 M - - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.08 B - - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
398 K - - $ 24.9 M usaUSA
Brickell Biotech Brickell Biotech
BBI
8.01 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
455 K - - $ 8.42 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
19.9 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
1.66 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
36.1 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
1.53 M - - $ 2.36 B usaUSA
Acasti Pharma Acasti Pharma
ACST
100 M - 4.01 % $ 150 M canadaCanada
Galapagos NV Galapagos NV
GLPG
1.11 B - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
1.1 M - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
1.4 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
2.04 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
5.06 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
1.5 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
2.05 M - - $ 35.3 M usaUSA
Metacrine Metacrine
MTCR
1.45 M - - $ 24.2 M usaUSA